SCHEDULE: Ming Hsieh Updates Fulgent Genetics Ownership Stake

CEO Ming Hsieh reports a change in beneficial ownership of Fulgent Genetics common stock following equity award vesting.

Summary

• Ming Hsieh, CEO and Chairperson of Fulgent Genetics, Inc., filed an amendment to his Schedule 13D regarding his beneficial ownership.
• The reporting person now beneficially owns 8,872,539 shares, representing 32.26% of the company's outstanding common stock.
• The increase in holdings resulted from the vesting of 5,496 shares of common stock from previously granted Restricted Stock Units (RSUs) on May 26, 2026.
• 2,949 shares were withheld for tax obligations related to the RSU vesting.
• The Ming Hsieh Trust continues to hold 7,895,115 shares, representing 28.72% of the company.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard equity compensation vesting and existing collateral arrangements.

Positives

• The CEO maintains a significant long-term equity stake of 32.26%, signaling strong alignment with shareholder interests.
• No cash consideration was required for the acquisition of the additional shares, as they were part of existing equity incentive plans.

Negatives

• A substantial portion of the shares held by the Trust (6,760,733 shares) are pledged as collateral for a credit facility and a pre-paid forward arrangement, creating potential liquidation risk if default occurs.

Risks

• The pledge of 6,760,733 shares as security for credit facilities means that in the event of a default, the lender could dispose of these shares, potentially impacting the market price.
• The reporting person retains the right to increase or decrease holdings based on market conditions, which may lead to future volatility.

Future Outlook

The reporting person intends to review ownership on a continuing basis and may increase or decrease holdings based on market conditions, business prospects, and personal financial considerations.

Management Comments

• The Reporting Person holds the shares of Common Stock reported in this Statement for general investment purposes.

Industry Context

StockSavvy.ai notes that high insider ownership is common in founder-led biotech firms, though the high volume of pledged shares is a specific governance factor that investors should monitor for potential forced liquidation risks.

Comparison to Industry Standards

• Insider ownership levels of 32.26% are significantly higher than the average for mid-cap healthcare companies, indicating strong founder commitment.
• The use of pledged shares as collateral is a standard but aggressive financial strategy that carries higher risk compared to unencumbered holdings.

Related Party Transactions

• The Ming Hsieh Trust, of which Mr. Hsieh is the trustee, holds a significant portion of the shares.
• The Dynasty Trust, where Mr. Hsieh and his spouse serve on the investment committee, holds 220,816 shares.

Stakeholder Impact

• Shareholders should be aware of the potential for large blocks of shares to be sold if the credit facilities secured by the pledged shares are triggered.

Next Steps

• Continued monitoring of the reporting person's Form 4 filings for any changes in pledged share status or further acquisitions/dispositions.

Key Dates

Keywords

Fulgent Genetics, FLGT, Ming Hsieh, Schedule 13D, Beneficial Ownership, Insider Trading, Equity Vesting